List of Tables
Table 1. Drugs for Vulvovaginal Candidiasis Market Trends
Table 2. Drugs for Vulvovaginal Candidiasis Market Drivers & Opportunity
Table 3. Drugs for Vulvovaginal Candidiasis Market Challenges
Table 4. Drugs for Vulvovaginal Candidiasis Market Restraints
Table 5. Global Drugs for Vulvovaginal Candidiasis Revenue by Company (2020-2025) & (US$ Million)
Table 6. Global Drugs for Vulvovaginal Candidiasis Revenue Market Share by Company (2020-2025)
Table 7. Global Drugs for Vulvovaginal Candidiasis Sales Volume by Company (2020-2025) & (K Units)
Table 8. Global Drugs for Vulvovaginal Candidiasis Sales Volume Market Share by Company (2020-2025)
Table 9. Global Market Drugs for Vulvovaginal Candidiasis Price by Company (2020-2025) & (USD/Unit)
Table 10. Key Manufacturers Drugs for Vulvovaginal Candidiasis Manufacturing Base and Headquarters
Table 11. Key Manufacturers Drugs for Vulvovaginal Candidiasis Product Type
Table 12. Key Manufacturers Time to Begin Mass Production of Drugs for Vulvovaginal Candidiasis
Table 13. Global Drugs for Vulvovaginal Candidiasis Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Top Manufacturers Market Share by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Drugs for Vulvovaginal Candidiasis as of 2024)
Table 15. Mergers & Acquisitions, Expansion Plans
Table 16. Global Drugs for Vulvovaginal Candidiasis Sales Value by Type: 2020 VS 2024 VS 2031 (US$ Million)
Table 17. Global Drugs for Vulvovaginal Candidiasis Sales Value by Type (2020-2025) & (US$ Million)
Table 18. Global Drugs for Vulvovaginal Candidiasis Sales Value by Type (2026-2031) & (US$ Million)
Table 19. Global Drugs for Vulvovaginal Candidiasis Sales Market Share in Value by Type (2020-2025)
Table 20. Global Drugs for Vulvovaginal Candidiasis Sales Market Share in Value by Type (2026-2031)
Table 21. Global Drugs for Vulvovaginal Candidiasis Sales Volume by Type: 2020 VS 2024 VS 2031 (K Units)
Table 22. Global Drugs for Vulvovaginal Candidiasis Sales Volume by Type (2020-2025) & (K Units)
Table 23. Global Drugs for Vulvovaginal Candidiasis Sales Volume by Type (2026-2031) & (K Units)
Table 24. Global Drugs for Vulvovaginal Candidiasis Sales Market Share in Volume by Type (2020-2025)
Table 25. Global Drugs for Vulvovaginal Candidiasis Sales Market Share in Volume by Type (2026-2031)
Table 26. Global Drugs for Vulvovaginal Candidiasis Price by Type (2020-2025) & (USD/Unit)
Table 27. Global Drugs for Vulvovaginal Candidiasis Price by Type (2026-2031) & (USD/Unit)
Table 28. Global Drugs for Vulvovaginal Candidiasis Sales Value by Application: 2020 VS 2024 VS 2031 (US$ Million)
Table 29. Global Drugs for Vulvovaginal Candidiasis Sales Value by Application (2020-2025) & (US$ Million)
Table 30. Global Drugs for Vulvovaginal Candidiasis Sales Value by Application (2026-2031) & (US$ Million)
Table 31. Global Drugs for Vulvovaginal Candidiasis Sales Market Share in Value by Application (2020-2025)
Table 32. Global Drugs for Vulvovaginal Candidiasis Sales Market Share in Value by Application (2026-2031)
Table 33. Global Drugs for Vulvovaginal Candidiasis Sales Volume by Application: 2020 VS 2024 VS 2031 (K Units)
Table 34. Global Drugs for Vulvovaginal Candidiasis Sales Volume by Application (2020-2025) & (K Units)
Table 35. Global Drugs for Vulvovaginal Candidiasis Sales Volume by Application (2026-2031) & (K Units)
Table 36. Global Drugs for Vulvovaginal Candidiasis Sales Market Share in Volume by Application (2020-2025)
Table 37. Global Drugs for Vulvovaginal Candidiasis Sales Market Share in Volume by Application (2026-2031)
Table 38. Global Drugs for Vulvovaginal Candidiasis Price by Application (2020-2025) & (USD/Unit)
Table 39. Global Drugs for Vulvovaginal Candidiasis Price by Application (2026-2031) & (USD/Unit)
Table 40. Global Drugs for Vulvovaginal Candidiasis Sales Value by Region, (2020 VS 2024 VS 2031) & (US$ Million)
Table 41. Global Drugs for Vulvovaginal Candidiasis Sales Value by Region (2020-2025) & (US$ Million)
Table 42. Global Drugs for Vulvovaginal Candidiasis Sales Value by Region (2026-2031) & (US$ Million)
Table 43. Global Drugs for Vulvovaginal Candidiasis Sales Value by Region (2020-2025) & (%)
Table 44. Global Drugs for Vulvovaginal Candidiasis Sales Value by Region (2026-2031) & (%)
Table 45. Global Drugs for Vulvovaginal Candidiasis Sales Volume by Region (K Units): 2020 VS 2024 VS 2031
Table 46. Global Drugs for Vulvovaginal Candidiasis Sales Volume by Region (2020-2025) & (K Units)
Table 47. Global Drugs for Vulvovaginal Candidiasis Sales Volume by Region (2026-2031) & (K Units)
Table 48. Global Drugs for Vulvovaginal Candidiasis Sales Volume by Region (2020-2025) & (%)
Table 49. Global Drugs for Vulvovaginal Candidiasis Sales Volume by Region (2026-2031) & (%)
Table 50. Global Drugs for Vulvovaginal Candidiasis Average Price by Region (2020-2025) & (USD/Unit)
Table 51. Global Drugs for Vulvovaginal Candidiasis Average Price by Region (2026-2031) & (USD/Unit)
Table 52. Key Countries/Regions Drugs for Vulvovaginal Candidiasis Sales Value Growth Trends, (US$ Million): 2020 VS 2024 VS 2031
Table 53. Key Countries/Regions Drugs for Vulvovaginal Candidiasis Sales Value, (2020-2025) & (US$ Million)
Table 54. Key Countries/Regions Drugs for Vulvovaginal Candidiasis Sales Value, (2026-2031) & (US$ Million)
Table 55. Key Countries/Regions Drugs for Vulvovaginal Candidiasis Sales Volume, (2020-2025) & (K Units)
Table 56. Key Countries/Regions Drugs for Vulvovaginal Candidiasis Sales Volume, (2026-2031) & (K Units)
Table 57. Bayer Company Information
Table 58. Bayer Introduction and Business Overview
Table 59. Bayer Drugs for Vulvovaginal Candidiasis Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 60. Bayer Drugs for Vulvovaginal Candidiasis Product Offerings
Table 61. Bayer Recent Development
Table 62. Perrigo Company Information
Table 63. Perrigo Introduction and Business Overview
Table 64. Perrigo Drugs for Vulvovaginal Candidiasis Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 65. Perrigo Drugs for Vulvovaginal Candidiasis Product Offerings
Table 66. Perrigo Recent Development
Table 67. J & J Company Information
Table 68. J & J Introduction and Business Overview
Table 69. J & J Drugs for Vulvovaginal Candidiasis Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 70. J & J Drugs for Vulvovaginal Candidiasis Product Offerings
Table 71. J & J Recent Development
Table 72. Pfizer Company Information
Table 73. Pfizer Introduction and Business Overview
Table 74. Pfizer Drugs for Vulvovaginal Candidiasis Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 75. Pfizer Drugs for Vulvovaginal Candidiasis Product Offerings
Table 76. Pfizer Recent Development
Table 77. Bristol-Myers Squibb Company Information
Table 78. Bristol-Myers Squibb Introduction and Business Overview
Table 79. Bristol-Myers Squibb Drugs for Vulvovaginal Candidiasis Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 80. Bristol-Myers Squibb Drugs for Vulvovaginal Candidiasis Product Offerings
Table 81. Bristol-Myers Squibb Recent Development
Table 82. Effik Company Information
Table 83. Effik Introduction and Business Overview
Table 84. Effik Drugs for Vulvovaginal Candidiasis Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 85. Effik Drugs for Vulvovaginal Candidiasis Product Offerings
Table 86. Effik Recent Development
Table 87. Teva Company Information
Table 88. Teva Introduction and Business Overview
Table 89. Teva Drugs for Vulvovaginal Candidiasis Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 90. Teva Drugs for Vulvovaginal Candidiasis Product Offerings
Table 91. Teva Recent Development
Table 92. Sanofi Company Information
Table 93. Sanofi Introduction and Business Overview
Table 94. Sanofi Drugs for Vulvovaginal Candidiasis Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 95. Sanofi Drugs for Vulvovaginal Candidiasis Product Offerings
Table 96. Sanofi Recent Development
Table 97. Cisen Pharmaceutical Company Information
Table 98. Cisen Pharmaceutical Introduction and Business Overview
Table 99. Cisen Pharmaceutical Drugs for Vulvovaginal Candidiasis Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 100. Cisen Pharmaceutical Drugs for Vulvovaginal Candidiasis Product Offerings
Table 101. Cisen Pharmaceutical Recent Development
Table 102. Kingyork Group Company Information
Table 103. Kingyork Group Introduction and Business Overview
Table 104. Kingyork Group Drugs for Vulvovaginal Candidiasis Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 105. Kingyork Group Drugs for Vulvovaginal Candidiasis Product Offerings
Table 106. Kingyork Group Recent Development
Table 107. Key Raw Materials Lists
Table 108. Raw Materials Key Suppliers Lists
Table 109. Drugs for Vulvovaginal Candidiasis Downstream Customers
Table 110. Drugs for Vulvovaginal Candidiasis Distributors List
Table 111. Research Programs/Design for This Report
Table 112. Key Data Information from Secondary Sources
Table 113. Key Data Information from Primary Sources
List of Figures
Figure 1. Drugs for Vulvovaginal Candidiasis Product Picture
Figure 2. Global Drugs for Vulvovaginal Candidiasis Sales Value, 2020 VS 2024 VS 2031 (US$ Million)
Figure 3. Global Drugs for Vulvovaginal Candidiasis Sales Value (2020-2031) & (US$ Million)
Figure 4. Global Drugs for Vulvovaginal Candidiasis Sales Volume (2020-2031) & (K Units)
Figure 5. Global Drugs for Vulvovaginal Candidiasis Sales Price (2020-2031) & (USD/Unit)
Figure 6. Drugs for Vulvovaginal Candidiasis Report Years Considered
Figure 7. Global Drugs for Vulvovaginal Candidiasis Players Revenue Ranking (2024) & (US$ Million)
Figure 8. Global Drugs for Vulvovaginal Candidiasis Players Sales Volume Ranking (2024) & (K Units)
Figure 9. The 5 and 10 Largest Manufacturers in the World: Market Share by Drugs for Vulvovaginal Candidiasis Revenue in 2024
Figure 10. Drugs for Vulvovaginal Candidiasis Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
Figure 11. Cream Picture
Figure 12. Pessary Picture
Figure 13. Other Picture
Figure 14. Global Drugs for Vulvovaginal Candidiasis Sales Value by Type (2020 VS 2024 VS 2031) & (US$ Million)
Figure 15. Global Drugs for Vulvovaginal Candidiasis Sales Value Market Share by Type, 2024 & 2031
Figure 16. Global Drugs for Vulvovaginal Candidiasis Sales Volume by Type (2020 VS 2024 VS 2031) & (K Units)
Figure 17. Global Drugs for Vulvovaginal Candidiasis Sales Volume Market Share by Type, 2024 & 2031
Figure 18. Global Drugs for Vulvovaginal Candidiasis Price by Type (2020-2031) & (USD/Unit)
Figure 19. Product Picture of Hospital & Clinic
Figure 20. Product Picture of Pharmacy
Figure 21. Global Drugs for Vulvovaginal Candidiasis Sales Value by Application (2020 VS 2024 VS 2031) & (US$ Million)
Figure 22. Global Drugs for Vulvovaginal Candidiasis Sales Value Market Share by Application, 2024 & 2031
Figure 23. Global Drugs for Vulvovaginal Candidiasis Sales Volume by Application (2020 VS 2024 VS 2031) & (K Units)
Figure 24. Global Drugs for Vulvovaginal Candidiasis Sales Volume Market Share by Application, 2024 & 2031
Figure 25. Global Drugs for Vulvovaginal Candidiasis Price by Application (2020-2031) & (USD/Unit)
Figure 26. North America Drugs for Vulvovaginal Candidiasis Sales Value (2020-2031) & (US$ Million)
Figure 27. North America Drugs for Vulvovaginal Candidiasis Sales Value by Country (%), 2024 VS 2031
Figure 28. Europe Drugs for Vulvovaginal Candidiasis Sales Value, (2020-2031) & (US$ Million)
Figure 29. Europe Drugs for Vulvovaginal Candidiasis Sales Value by Country (%), 2024 VS 2031
Figure 30. Asia Pacific Drugs for Vulvovaginal Candidiasis Sales Value, (2020-2031) & (US$ Million)
Figure 31. Asia Pacific Drugs for Vulvovaginal Candidiasis Sales Value by Region (%), 2024 VS 2031
Figure 32. South America Drugs for Vulvovaginal Candidiasis Sales Value, (2020-2031) & (US$ Million)
Figure 33. South America Drugs for Vulvovaginal Candidiasis Sales Value by Country (%), 2024 VS 2031
Figure 34. Middle East & Africa Drugs for Vulvovaginal Candidiasis Sales Value, (2020-2031) & (US$ Million)
Figure 35. Middle East & Africa Drugs for Vulvovaginal Candidiasis Sales Value by Country (%), 2024 VS 2031
Figure 36. Key Countries/Regions Drugs for Vulvovaginal Candidiasis Sales Value (%), (2020-2031)
Figure 37. Key Countries/Regions Drugs for Vulvovaginal Candidiasis Sales Volume (%), (2020-2031)
Figure 38. United States Drugs for Vulvovaginal Candidiasis Sales Value, (2020-2031) & (US$ Million)
Figure 39. United States Drugs for Vulvovaginal Candidiasis Sales Value by Type (%), 2024 VS 2031
Figure 40. United States Drugs for Vulvovaginal Candidiasis Sales Value by Application (%), 2024 VS 2031
Figure 41. Europe Drugs for Vulvovaginal Candidiasis Sales Value, (2020-2031) & (US$ Million)
Figure 42. Europe Drugs for Vulvovaginal Candidiasis Sales Value by Type (%), 2024 VS 2031
Figure 43. Europe Drugs for Vulvovaginal Candidiasis Sales Value by Application (%), 2024 VS 2031
Figure 44. China Drugs for Vulvovaginal Candidiasis Sales Value, (2020-2031) & (US$ Million)
Figure 45. China Drugs for Vulvovaginal Candidiasis Sales Value by Type (%), 2024 VS 2031
Figure 46. China Drugs for Vulvovaginal Candidiasis Sales Value by Application (%), 2024 VS 2031
Figure 47. Japan Drugs for Vulvovaginal Candidiasis Sales Value, (2020-2031) & (US$ Million)
Figure 48. Japan Drugs for Vulvovaginal Candidiasis Sales Value by Type (%), 2024 VS 2031
Figure 49. Japan Drugs for Vulvovaginal Candidiasis Sales Value by Application (%), 2024 VS 2031
Figure 50. South Korea Drugs for Vulvovaginal Candidiasis Sales Value, (2020-2031) & (US$ Million)
Figure 51. South Korea Drugs for Vulvovaginal Candidiasis Sales Value by Type (%), 2024 VS 2031
Figure 52. South Korea Drugs for Vulvovaginal Candidiasis Sales Value by Application (%), 2024 VS 2031
Figure 53. Southeast Asia Drugs for Vulvovaginal Candidiasis Sales Value, (2020-2031) & (US$ Million)
Figure 54. Southeast Asia Drugs for Vulvovaginal Candidiasis Sales Value by Type (%), 2024 VS 2031
Figure 55. Southeast Asia Drugs for Vulvovaginal Candidiasis Sales Value by Application (%), 2024 VS 2031
Figure 56. India Drugs for Vulvovaginal Candidiasis Sales Value, (2020-2031) & (US$ Million)
Figure 57. India Drugs for Vulvovaginal Candidiasis Sales Value by Type (%), 2024 VS 2031
Figure 58. India Drugs for Vulvovaginal Candidiasis Sales Value by Application (%), 2024 VS 2031
Figure 59. Drugs for Vulvovaginal Candidiasis Industrial Chain
Figure 60. Drugs for Vulvovaginal Candidiasis Manufacturing Cost Structure
Figure 61. Channels of Distribution (Direct Sales, and Distribution)
Figure 62. Bottom-up and Top-down Approaches for This Report
Figure 63. Data Triangulation
Figure 64. Key Executives Interviewed
